Multiple Myeloma Treatment Landscape from 2011 to 2016 in Alberta, Canada: Results From the Population-Based “Identifying Outcomes in Real-World Multiple Myeloma” (INFORMM) Study
Building on the Methodology Poster presented at the 2019 CADTH Symposium, we will be presenting results on treatment patterns for multiple myeloma (MM) in Alberta from the INFORMM Study at the 24th Congress of the European Hematology Association (EHA) from June 13-16, 2019 in Amsterdam.
The treatment landscape of MM is rapidly evolving with the availability of new therapeutic options leading to improved responses and survival rates. The INFORMM study from Alberta, Canada (population of 4.3 million in 2018) examined treatment patterns in a real-world setting using population-based administrative data to better understand the management of newly diagnosed multiple myeloma (NDMM) and patient outcomes in the era of novel therapies.
The study cohort consisted of 1,377 patients (828 men, 549 women). The mean age at diagnosis was 68.9 ± 12.2 years and mean follow-up time was 2.3 ± 1.6 years. Our findings showed that among patients with NDMM who were receiving treatment, approximately 24% had autologous stem cell transplant (ASCT) and 76% did not. In addition, patients who had ASCT appeared to be more “fit” as indicated by mean age, comorbidity index, and ISS stage compared with patients who did not have ASCT. Treatment attrition rates were similar in both the ASCT and non-ASCT cohorts, although attrition rates were higher in the non-ASCT group in subsequent lines of therapy. Notably, patients were seen to benefit from post-ASCT maintenance therapy.
To our knowledge, this is the first population-based study utilizing administrative health data to examine the treatment landscape in an NDMM population in Alberta, Canada in the era of novel therapies. High treatment attrition rates emphasize the importance of optimizing first-line treatment opportunities.
Interested in learning more? Please see the poster presented by Dr. Victor Jimenez-Zepeda at the 24th EHA Congress. Check it out here: INFORMM Study EHA 2019 and Contact Us to learn how Medlior can support your next research project.